MELISSA WHITE: Open Payments
NPI 1033643432 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$756 in 40 payments from 9 companies in 2025. Trend: 2023 $208 · 2024 $420 · 2025 $756
Food & beverage: $756
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 18 | $380 |
| ViiV Healthcare Company | 11 | $142 |
| Merck Sharp & Dohme LLC | 4 | $96 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
| Abbott Laboratories | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
| ABBVIE INC. | 1 | $14 |
Products named: PIFELTRO, DOVATO, Biktarvy, APRETUDE, XIFAXAN, PROCLAIM, TRINTELLIX, FARXIGA.
Industry payments across MS — which companies pay providers there.
